2-Isopropyl-3,3'-spirobi<3H-naphtho<2,1-b>pyran> | 10487-40-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: 2-Isopropyl-3,3'-spirobi<3H-naphtho<2,1-b>pyran>
• 英文别名: 2'-Propan-2-yl-3,3'-spirobi[benzo[f]chromene]
• CAS: 10487-40-8
• 化学式: C₂₈H₂₂O₂
• 分子量: 390.481
• InChiKey: YCTDUCBNQDFVIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  30
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-甲基-2-戊酮 、 2-羟基-1-萘甲醛 在 盐酸 、 乙醇 作用下， 生成 2-Isopropyl-3,3'-spirobi<3H-naphtho<2,1-b>pyran>
  参考文献：
  名称：

  Mid-term Results of the Ross Procedure

  摘要：

  Although the Ross procedure has been performed for over three decades, its role in the management of patients with aortic valve disease is not well established. This study reviews our experience with this operation. From 1990 to 1999, 155 patients underwent the Ross procedure. The mean age of 106 men and 49 women was 35 years. Most patients (85%) had congenital aortic valve disease. The pulmonary autograft was implanted in the subcoronary position in 2 patients, as an aortic root inclusion in 78, and aortic root replacement in 75. The follow-up extended from 9 to 114 months, mean of 45 +/- 28 months, and it was complete. All patients have had Doppler echocardiographic studies. There was only one operative and one late death. The survival was 98% at 7 years. The freedom from 3+ or 4+ aortic insufficiency was 86% at 7 years and the freedom from reoperation on the pulmonary autograft was 95% at 7 years. Dilation of the aortic annulus and/or sinotubular junction was the most common cause of aortic insufficiency. One patient required three reoperations on the biological pulmonary valve. Most patients (96%) have no cardiac symptoms. The Ross procedure has provided excellent functional results in most patients, but progressive aortic insufficiency due to dilation of the aortic annulus and/or sinotubular junction is a potential problem in a number of patients.

  DOI：

  10.1111/j.1540-8191.2001.tb00533.x

文献信息

• US5551973A
  申请人：——

  公开号：US5551973A

  公开（公告）日：1996-09-03
• US5593486A
  申请人：——

  公开号：US5593486A

  公开（公告）日：1997-01-14
• US5633109A
  申请人：——

  公开号：US5633109A

  公开（公告）日：1997-05-27
• Mid-term Results of the Ross Procedure
  作者：Domenico Paparella、Tirone E. David、Susan Armstrong、Joan Ivanov

  DOI：10.1111/j.1540-8191.2001.tb00533.x

  日期：2001.7

  Although the Ross procedure has been performed for over three decades, its role in the management of patients with aortic valve disease is not well established. This study reviews our experience with this operation. From 1990 to 1999, 155 patients underwent the Ross procedure. The mean age of 106 men and 49 women was 35 years. Most patients (85%) had congenital aortic valve disease. The pulmonary autograft was implanted in the subcoronary position in 2 patients, as an aortic root inclusion in 78, and aortic root replacement in 75. The follow-up extended from 9 to 114 months, mean of 45 +/- 28 months, and it was complete. All patients have had Doppler echocardiographic studies. There was only one operative and one late death. The survival was 98% at 7 years. The freedom from 3+ or 4+ aortic insufficiency was 86% at 7 years and the freedom from reoperation on the pulmonary autograft was 95% at 7 years. Dilation of the aortic annulus and/or sinotubular junction was the most common cause of aortic insufficiency. One patient required three reoperations on the biological pulmonary valve. Most patients (96%) have no cardiac symptoms. The Ross procedure has provided excellent functional results in most patients, but progressive aortic insufficiency due to dilation of the aortic annulus and/or sinotubular junction is a potential problem in a number of patients.